张倩

[摘要] 目的 探讨参松养心胶囊治疗冠心病心功能不全气虚血瘀型的临床疗效及安全性。 方法 80例冠心病心功能不全气虚型的患者随机分为对照组与观察组各40例。对照组予西医常规治疗，观察组在此基础上给予参松养心胶囊。比较两组患者的疗效、治疗前后6min步行试验、治疗前后心电图及ESV、EDV与LVEF及安全性。 结果 对照组的总有效率为72.50%（29/40），显著低于观察组92.50%（37/40）（P<0.05）；观察组治疗后6min步行试验与对照组比较，P<0.05；两组治疗后ESV、EDV及LVEF相比，P<0.05。 结论 参松养心胶囊治疗冠心病心功能不全气虚血瘀型的临床疗效显著。

[关键词] 参松养心胶囊；冠心病心功能不全；气虚血瘀型；临床疗效；安全性

[中图分类号] R259 [文献标识码] B [文章编号] 2095-0616（2014）04-116-03

The clinical efficacy and safety of Shensongyangxin capsules in treating coronary heart disease heart failure with qi deficiency and blood stasis syndrome

ZHANG Qian

Department of Internal Medicine， Shengli Petroleum Administrative Bureau Supply Hospital， Dongying 257000， China

[Abstract] Objective To explore the clinical efficacy and safety of Shensongyangxin capsules in treating coronary heart disease heart failure with qi deficiency and blood stasis syndrome. Methods Eighty coronary heart disease patients with heart failure and qi deficiency syndrome were chosen and randomly divided into two groups of 40 patients： the control group and the observation group. Patients in the control group were treated by routine western medicine， while patients in the observation group were treated by Shensongyangxin capsules in addition to routine western medicine. The clinical efficacy， the 6-minute walking test results， the electrocardiogram， ESV， EDV and LVEF before and after the treatment， and the safety of the two groups were compared. Results The total effective rate of control group was 72.50%（29/40）， which was significantly lower than that of the observation group 92.50%（37/40） （P<0.05）； The observation group and the control group were significantly different in the 6-minute walking test （P<0.05）； The two groups were significantly different in the post-treatment ESV， EDV and LVEF （P<0.05）. Conclusion Shensongyangxin capsules had significant clinical effect in treating coronary heart disease heart failure with qi deficiency and blood stasis syndrome.

[Key words] Shensongyangxin capsules；Coronary heart disease heart failure；Qi deficiency and blood stasis syndrome；Clinical efficacy；Safety

冠心病的致残率以及临床致死率极高，严重影响患者的生存质量及预后[1]。本研究回顾性分析2009年9月～2013年9月入住我院的冠心病心功能不全气虚血瘀型患者的临床资料，旨在探讨参松养心胶囊的临床疗效，现报道如下。

1 资料与方法

1.1 一般资料

回顾性分析2009年9月～2013年9月入住我院的80例冠心病心功能不全气虚血瘀型患者的临床资料，西医诊断标准参照Framingham心力衰竭诊断标准及美国纽约心脏病学会（NYHA）心功能分级标准制定[2]。排除急性心功能不全、心功能为Ⅳ级、急性心梗、心源性休克及未控制的高血压、未控制的感染、妊娠期或者哺乳期妇女；且不愿签署诊疗知情同意书者。随机分对照组与观察组各40例。对照组男23例，女17例；年龄34～75岁，平均（58.1±7.3）岁；病程1～15年，平均（6.0±2.3）年。观察组男24例，女16例；年龄33～77岁，平均（59.2±8.1）岁；病程2～16年，平均（6.4±2.5）年。两组患者一般资料比较，差异无统计学意义（P>0.05），具有可比性。

1.2 纳入标准

符合冠心病慢性心功能不全的临床诊断标准，心功能Ⅱ～Ⅲ级；……